Venbio Select Advisor Llc decreased its stake in Agenus Inc (AGEN) by 71.12% based on its latest 2018Q1 regulatory filing with the SEC. Venbio Select Advisor Llc sold 1.74 million shares as the company’s stock declined 32.76% with the market. The institutional investor held 704,554 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $3.32 million, down from 2.44M at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Agenus Inc for a number of months, seems to be less bullish one the $354.64M market cap company. The stock increased 0.59% or $0.02 during the last trading session, reaching $3.41. About 1.39M shares traded. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since May 30, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.
Yorktown Management & Research Co Inc decreased its stake in Validus Holdings Ltd. (VR) by 55% based on its latest 2018Q1 regulatory filing with the SEC. Yorktown Management & Research Co Inc sold 5,500 shares as the company’s stock rose 0.24% while stock markets declined. The institutional investor held 4,500 shares of the finance company at the end of 2018Q1, valued at $304,000, down from 10,000 at the end of the previous reported quarter. Yorktown Management & Research Co Inc who had been investing in Validus Holdings Ltd. for a number of months, seems to be less bullish one the $5.56 billion market cap company. The stock increased 0.25% or $0.17 during the last trading session, reaching $67.75. About 1.31 million shares traded or 83.13% up from the average. Validus Holdings, Ltd. (NYSE:VR) has risen 26.41% since May 30, 2017 and is uptrending. It has outperformed by 13.84% the S&P500.
Investors sentiment decreased to 0.76 in Q1 2018. Its down 0.17, from 0.93 in 2017Q4. It dived, as 56 investors sold VR shares while 74 reduced holdings. 62 funds opened positions while 37 raised stakes. 60.91 million shares or 19.41% less from 75.58 million shares in 2017Q4 were reported. Panagora Asset Management Inc has invested 0.02% in Validus Holdings, Ltd. (NYSE:VR). Blackrock has 0.01% invested in Validus Holdings, Ltd. (NYSE:VR) for 3.53M shares. Naples Glob Advisors Ltd Llc holds 0.1% of its portfolio in Validus Holdings, Ltd. (NYSE:VR) for 4,925 shares. Signaturefd Ltd Company has 0.01% invested in Validus Holdings, Ltd. (NYSE:VR). Alpine Associates Mgmt Incorporated accumulated 1.73M shares or 3.84% of the stock. Cap Fund Mngmt Sa holds 0.02% in Validus Holdings, Ltd. (NYSE:VR) or 56,836 shares. Vident Investment Advisory Lc invested in 0.02% or 6,989 shares. Cornerstone Cap Inc reported 3.61% stake. Eulav Asset Mgmt accumulated 34,200 shares or 0.11% of the stock. Stone Ridge Asset Management Ltd reported 0.15% in Validus Holdings, Ltd. (NYSE:VR). Water Island Cap Ltd Com has invested 2.7% in Validus Holdings, Ltd. (NYSE:VR). Vanguard Grp Inc invested 0.02% in Validus Holdings, Ltd. (NYSE:VR). S Muoio & Ltd Llc, a New York-based fund reported 87,000 shares. Millennium Mgmt holds 0.01% of its portfolio in Validus Holdings, Ltd. (NYSE:VR) for 76,814 shares. C V Starr And Co owns 40,001 shares for 12.83% of their portfolio.
Since December 15, 2017, it had 0 insider buys, and 8 sales for $3.87 million activity. 10,310 shares were sold by Carpenter Michael E.A., worth $697,781.
Yorktown Management & Research Co Inc, which manages about $931.40 million and $337.68 million US Long portfolio, upped its stake in Astrazeneca Plc (NYSE:AZN) by 28,800 shares to 38,800 shares, valued at $1.36M in 2018Q1, according to the filing. It also increased its holding in Wal (NYSE:WMT) by 5,000 shares in the quarter, for a total of 35,000 shares, and has risen its stake in Rio Tinto Plc (NYSE:RIO).
Analysts await Validus Holdings, Ltd. (NYSE:VR) to report earnings on July, 26. They expect $1.24 earnings per share, up 13.76% or $0.15 from last year’s $1.09 per share. VR’s profit will be $101.84M for 13.66 P/E if the $1.24 EPS becomes a reality. After $0.53 actual earnings per share reported by Validus Holdings, Ltd. for the previous quarter, Wall Street now forecasts 133.96% EPS growth.
Among 9 analysts covering Validus Holdings (NYSE:VR), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Validus Holdings had 20 analyst reports since July 21, 2015 according to SRatingsIntel. Buckingham Research initiated Validus Holdings, Ltd. (NYSE:VR) rating on Monday, September 11. Buckingham Research has “Buy” rating and $52.0 target. The firm has “Hold” rating given on Friday, April 28 by Wood. On Friday, September 23 the stock rating was downgraded by UBS to “Neutral”. The stock of Validus Holdings, Ltd. (NYSE:VR) has “Neutral” rating given on Monday, October 30 by UBS. The firm has “Overweight” rating given on Tuesday, June 28 by JP Morgan. Buckingham Research downgraded the stock to “Neutral” rating in Tuesday, February 13 report. The rating was downgraded by JMP Securities to “Hold” on Tuesday, January 30. Bank of America upgraded the stock to “Neutral” rating in Monday, May 2 report. The firm earned “Market Perform” rating on Tuesday, January 23 by Wood. Keefe Bruyette & Woods upgraded the stock to “Buy” rating in Thursday, January 4 report.
More recent Validus Holdings, Ltd. (NYSE:VR) news were published by: Gurufocus.com which released: “Non-Value Investor Paul Tudor Jones’ Top 5 Buys of 1st Quarter” on May 24, 2018. Also Businesswire.com published the news titled: “Talbot Expands Construction Team with Appointment in Singapore” on May 24, 2018. Streetinsider.com‘s news article titled: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” with publication date: May 15, 2018 was also an interesting one.
Among 5 analysts covering Agenus (NASDAQ:AGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel. As per Tuesday, October 27, the company rating was downgraded by Maxim Group. The stock has “Buy” rating by Jefferies on Friday, July 29. On Thursday, October 27 the stock rating was maintained by Maxim Group with “Buy”. As per Wednesday, December 16, the company rating was initiated by Jefferies. Maxim Group upgraded Agenus Inc. (NASDAQ:AGEN) on Friday, March 11 to “Buy” rating. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The company was maintained on Monday, July 27 by MLV. The firm has “Buy” rating given on Monday, June 26 by Jefferies. The firm has “Neutral” rating given on Friday, October 28 by H.C. Wainwright. The stock of Agenus Inc. (NASDAQ:AGEN) earned “Buy” rating by Jefferies on Thursday, August 3.
Investors sentiment increased to 1.46 in Q1 2018. Its up 0.20, from 1.26 in 2017Q4. It increased, as 11 investors sold AGEN shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported. Vident Investment Advisory Lc owns 484,930 shares for 0.09% of their portfolio. The New York-based Virtu Fincl Llc has invested 0.02% in Agenus Inc. (NASDAQ:AGEN). Gsa Capital Prtnrs Llp invested in 0% or 13,900 shares. Goldman Sachs Group stated it has 0% in Agenus Inc. (NASDAQ:AGEN). Lpl Ltd Liability Company has 26,174 shares. New York-based Fincl Bank Of Mellon has invested 0% in Agenus Inc. (NASDAQ:AGEN). Amalgamated Natl Bank holds 0% or 10,245 shares in its portfolio. Moreover, Citigroup has 0% invested in Agenus Inc. (NASDAQ:AGEN). Victory Cap Management reported 0% in Agenus Inc. (NASDAQ:AGEN). Ingalls And Snyder Limited Liability Corporation has invested 0% in Agenus Inc. (NASDAQ:AGEN). Ameritas Prtn holds 0% or 5,577 shares in its portfolio. Schwab Charles Invest Management stated it has 349,020 shares or 0% of all its holdings. Rhumbline Advisers accumulated 70,996 shares. Renaissance Tech Ltd Liability Corporation holds 1.88 million shares or 0.01% of its portfolio. Jump Trading Ltd Com holds 13,902 shares or 0.01% of its portfolio.
Venbio Select Advisor Llc, which manages about $380.08M and $2.09B US Long portfolio, upped its stake in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 800,000 shares to 4.69M shares, valued at $11.22M in 2018Q1, according to the filing. It also increased its holding in Array Biopharma Inc (NASDAQ:ARRY) by 1.85 million shares in the quarter, for a total of 1.92M shares, and has risen its stake in Argenx Se.
More important recent Agenus Inc. (NASDAQ:AGEN) news were published by: Fool.com which released: “Is Agenus Inc. (AGEN) a Buy?” on May 12, 2018, also Seekingalpha.com published article titled: “Agenus: Buy, Sell Or Hold?”, Seekingalpha.com published: “Agenus reports Q1 results; provides milestones for 2018” on May 07, 2018. More interesting news about Agenus Inc. (NASDAQ:AGEN) was released by: Seekingalpha.com and their article: “Agenus’ (AGEN) CEO Garo Armen on Q1 2018 Results – Earnings Call Transcript” with publication date: May 07, 2018.
Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on August, 2. They expect $-0.42 EPS, down 31.25% or $0.10 from last year’s $-0.32 per share. After $-0.42 actual EPS reported by Agenus Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
The post Yorktown Management & Research Co Has Trimmed Position in Validus Holdings LTD (VR) by $368,500 as Market Value Rose; As Agenus (AGEN) Share Value Declined, Venbio Select Advisor Cut by $6.94 Million Its Position appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/05/30/yorktown-management-as-agenus-agen-share-value-declined-venbio-select-advisor-cut-by-6-94-million/
No comments:
Post a Comment